Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
about
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.Coexistence of YWHAZ amplification predicts better prognosis in muscle-invasive bladder cancer with CDKN2A or TP53 loss.Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinomaTp53 and its potential therapeutic role as a target in bladder cancer.Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma.Recent progress with next-generation biomarkers in muscle-invasive bladder cancer.The evolving genomic landscape of urothelial carcinoma.Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic.A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma.Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance.Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities.Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer.Genomic profiling of advanced bladder cancer to guide the use of targeted therapeutics.Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?
P2860
Q33889152-48A4AFD8-2560-4380-B69C-6B57BF484435Q37376373-C8D8FC9A-C8DB-4A13-8281-E4AD186A3C56Q37588485-9F0E12EC-229D-4C0C-8D21-DA1904672359Q38436074-5106907D-91DA-4D3F-9E81-F00B0DD3BCB7Q38810603-E5308BFA-25E4-4596-BEA8-5D5A76CB942CQ38946859-C02E4910-0022-4B40-90D8-6EB65416D92AQ39124491-6CB805B9-61E8-424F-8214-FDB86B775BB4Q39237394-B8C2CF6F-92DC-438D-A81E-C4FC06AA4E8EQ40954926-879AE58B-B534-43AB-833C-1EA9C02B6233Q45977883-629D11FB-D937-4E8D-A2D0-C622518D2BF5Q47926486-67078458-E4FE-4342-B102-838A516D5146Q48205560-72838E41-42D0-4009-91F7-E8398FE9DCF8Q49456418-A19269A5-0C9C-490E-AB4D-FAAE97F7E8C1Q50064748-F58F54F3-12CA-4E99-A2A8-BC6E37167297Q50237607-0A76C20C-1A16-4251-8C0F-6B51DBF155FEQ55064633-3CCCC22C-2BDC-4C7C-AF05-B0C32F26D04C
P2860
Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Comprehensive genomic profilin ...... relevant genomic alterations.
@ast
Comprehensive genomic profilin ...... relevant genomic alterations.
@en
type
label
Comprehensive genomic profilin ...... relevant genomic alterations.
@ast
Comprehensive genomic profilin ...... relevant genomic alterations.
@en
prefLabel
Comprehensive genomic profilin ...... relevant genomic alterations.
@ast
Comprehensive genomic profilin ...... relevant genomic alterations.
@en
P2093
P2860
P356
P1433
P1476
Comprehensive genomic profilin ...... relevant genomic alterations.
@en
P2093
Badar Mian
Depinder Khaira
Doron Lipson
Huge A G Fisher
Jeffrey S Ross
Julia A Elvin
Norma Palma
Philip J Stephens
Roman Yelensky
P2860
P304
P356
10.1002/CNCR.29826
P407
P577
2015-12-09T00:00:00Z